OLITIGALTIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H30F2N6O8S
Molecular Weight	648.635
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@@H]([C@H]2O)N3C=C(N=N3)C4=CC=CC(F)=C4)[C@H](O)[C@H]([C@H]1O)N5C=C(N=N5)C6=CC=CC(F)=C6

InChI

InChIKey=YGIDGBAHDZEYMT-MQFIMZJJSA-N

InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://galecto.com/fda-approves-an-ind-from-galecto-biotech-for-td139-treatment-of-ipf-patients/ | https://www.ncbi.nlm.nih.gov/pubmed/27416897 | http://adisinsight.springer.com/drugs/800041385

TD139 is a highly potent, specific inhibitor of the galactoside binding pocket of galectin-3. TD139 is formulated for inhalation, which enables direct targeting the fibrotic tissue in the lungs, while minimizing systemic exposure. TD139 was initially developed by a team of scientists from Lund University, Sweden, and Edinburgh University, the UK. TD-139 is in phase I/II clinical trials for the treatment of idiopathic pulmonary fibrosis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Galectin-3 1 Target ID: CHEMBL4531 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27416897 \| https://www.ncbi.nlm.nih.gov/pubmed/22095546	Inhibitor 8504		14.0 nM [Kd]
Galectin-1 3 Target ID: CHEMBL4915 Sources: https://www.medchemexpress.com/TD139.html \| https://www.ncbi.nlm.nih.gov/pubmed/27416897	Inhibitor 8504		0.22 µM [Kd]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Idiopathic pulmonary fibrosis 10 Sources: https://clinicaltrials.gov/ct2/show/NCT02257177 http://galecto.com/fda-approves-an-ind-from-galecto-biotech-for-td139-treatment-of-ipf-patients/	Primary		Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
22.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33214209/	10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TD-139 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
82.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33214209/	10 mg 1 times / day multiple, respiratory dose: 10 mg route of administration: Respiratory experiment type: MULTIPLE co-administered:		TD-139 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
184.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33214209/	10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered:		TD-139 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1150 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33214209/	10 mg 1 times / day multiple, respiratory dose: 10 mg route of administration: Respiratory experiment type: MULTIPLE co-administered:		TD-139 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33214209/	10 mg single, respiratory dose: 10 mg route of administration: Respiratory experiment type: SINGLE co-administered:	TD-139 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/33214209/	10 mg 1 times / day multiple, respiratory dose: 10 mg route of administration: Respiratory experiment type: MULTIPLE co-administered:	TD-139 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED
7 h EXPERIMENT https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A7560	10 mg 1 times / day multiple, respiratory dose: 10 mg route of administration: Respiratory experiment type: MULTIPLE co-administered:	TD-139 plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P01EOM0	https://www.1pchem.com/search?query=1P01EOM0
AbovChem LLC	HY-19940	http://www.abovchem.com/pc/en/product_list.aspx?wd=HY-19940
AChemBlock	Q70190	http://www.achemblock.com/catalogsearch/result/?q=Q70190
ApexBio Technology	B8329	https://www.apexbt.com/catalogsearch/result/?q=B8329
AstaTech	C72753	http://astatechinc.com/CPSResult.php?CRNO=C72753
ChemShuttle	186295	https://www.chemshuttle.com/catalogsearch/result/?q=186295
eMolecules	76742463	https://orderbb.emolecules.com/search/#?query=76742463
Excenen	EX-A1688	http://www.excenen.com/searchresultlist.php?id=EX-A1688
mcule	MCULE-2711304312	https://mcule.com/MCULE-2711304312/
Molnova	M11938	https://www.molnova.com/en/serch-list.html?keywords=M11938
MolPort	MolPort-046-417-276	https://www.molport.com/shop/molecule-link/MolPort-046-417-276
MuseChem	I009529	https://www.musechem.com/product/I009529.html
TargetMol	T5121	https://www.targetmol.com/search?keyword=T5121

PubMed

Title	Date	PubMed
Galectin-3 endocytosis by carbohydrate independent and dependent pathways in different macrophage like cell types.	2012-07	22450157
Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice.	2012-06	22213244
Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3.	2012-03-01	22095546

Patents

Sample Use Guides

In Vivo Use Guide

TD139 is delivered to the lungs of IPF patients using the Plastiape inhaler device at the following 3 doses: 0.3mg, 3mg, and 10mg.

Route of Administration: Respiratory

In Vitro Use Guide

Primary alveolar epithelial cells from wild-type (WT) mice were plated and treated with transforming growth factor (TGF)-b1 in the presence or absence of 10 uM TD-139. TD-139 (10 uM) blocked TGF-b1–induced b-catenin phosphorylation as judged by Western blot analysis.

Name

Type

Language

TD139

Preferred Name

English

OLITIGALTIN

Official Name

English

olitigaltin [INN]

Common Name

English

TD-139

Code

English

BIS(3-DEOXY-3-(3-FLUOROPHENYL-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL)SULFANE

Systematic Name

English

.BETA.-D-GALACTOPYRANOSIDE, 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-.BETA.-D-GALACTOPYRANOSYL 3-DEOXY-3-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1-THIO-

Systematic Name

English

3,3'-DIDEOXY-3,3'-BIS-(4-(3-FLUOROPHENYL)-1H-1,2,3-TRIAZOL-1-YL)-1,1'-SULFANEDIYL-DI-.BETA.- D-GALACTOPYRANOSIDE

Common Name

English

GB0139

Code

English

TD 139 [WHO-DD]

Common Name

English

GB-0139

Code

English

OLITIGALTIN [USAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

757320